keyword
MENU ▼
Read by QxMD icon Read
search

gliclazide

keyword
https://www.readbyqxmd.com/read/29784014/unintentional-sulfonylurea-toxicity-due-to-a-drug-drug-interaction-a-case-report
#1
Keith Gunaratne, Emily Austin, Peter E Wu
BACKGROUND: Sulfonylureas are widely used for type 2 diabetes mellitus, but these medications carry a risk of hypoglycemia. Drug-drug interactions that inhibit sulfonylurea metabolism and thus increase systemic exposure can cause unintentional sulfonylurea toxicity. CASE PRESENTATION: A 56-year-old man presented with severe, recurrent hypoglycemia. He had a history of type 2 diabetes mellitus and was taking the sulfonylurea gliclazide with no prior episodes of hypoglycemia...
May 21, 2018: BMC Research Notes
https://www.readbyqxmd.com/read/29772022/binding-of-sulphonylureas-to-plasma-proteins-a-katp-channel-perspective
#2
Peter Proks, Holger Kramer, Elizabeth Haythorne, Frances M Ashcroft
Sulphonylurea drugs stimulate insulin secretion from pancreatic β-cells primarily by inhibiting ATP sensitive potassium (KATP) channels in the β-cell membrane. The effective sulphonylurea concentration at its site of action is significantly attenuated by binding to serum albumin, which makes it difficult to compare in vitro and in vivo data. We therefore measured the ability of gliclazide and glibenclamide to inhibit KATP channels and stimulate insulin secretion in the presence of serum albumin. We used this data, together with estimates of free drug concentrations from binding studies, to predict the extent of sulphonylurea inhibition of KATP channels at therapeutic concentrations in vivo...
2018: PloS One
https://www.readbyqxmd.com/read/29728041/-effect-and-mechanism-of-aerial-parts-of-salvia-miltiorrhiza-effective-constituents-on-glycolipid-metabolism-of-high-sugar-induced-drosophila-melanogaster-metabolic-disorder-model
#3
Chen-Yadai Yu, Jin-Gao Yu, Jun-Fei Gu, Shu-Lan Su, Yong-Qing Hua, Jin-Ao Duan
To evaluate the effect and mechanism of aerial parts of Salvia miltiorrhiza(SM) on high sugar-induced Drosophila melanogaster metabolic disorder model. The levels of glucose, triglyceride and protein in SM were detected; nymphosis time was recorded, and the reliability of metabolic disorder model as well as the mechanism of aerial parts of SM were evaluated based on metabonomics. The results showed that the levels of glucose and triglyceride in model group were significantly higher than those in normal control group( P <0...
April 2018: Zhongguo Zhong Yao za Zhi, Zhongguo Zhongyao Zazhi, China Journal of Chinese Materia Medica
https://www.readbyqxmd.com/read/29720769/the-influence-of-physical-division-of-tablets-on-the-variability-of-release-kinetics-of-gliclazide
#4
Dorota Wójcik-Pastuszka, Anna M Biedrawa, Dorota Haznar-Garbacz, Witold S Musiał
Tablets are often used in splitting process when the appropriated, registered dose is not available on the market or patients exhibit swallowing difficulties caused by the size of the tablet. The aim of the work was to assess the impact of physical division of tablets on the kinetics of in vitro gliclazide release from the intact and divided tablets. Gliclazide was released from prolonged release tablets containing 30 or 60 mg of the drug into a phosphate buffer, pH 7.4 and the amount of the drug in acceptor fluid was determined by UV-Vis spectrophotometry...
2018: Monatshefte Für Chemie
https://www.readbyqxmd.com/read/29710525/balanites-aegyptiaca-ameliorates-insulin-secretion-and-decreases-pancreatic-apoptosis-in-diabetic-rats-role-of-sapk-jnk-pathway
#5
Kamel M A Hassanin, Mohamed O Mahmoud, Hossam M Hassan, Abdel-Razik H Abdel-Razik, Lourin N Aziz, Mostafa E Rateb
SAPK-JNK pathway performs a significant role in the pathogenesis of type 2 diabetes. Balanites aegyptiaca (BA) is used as an anti-diabetic agent in folk medicine however its hypoglycemic mechanism is not fully elucidated. The current study aimed to evaluate the effect of crude extract, butanol, and dichloromethane fractions from BA on the stress-activated protein kinase/c-Jun N-terminal kinase (SAPK-JNK) pathway in experimental diabetic rats. Six groups of male Wistar rats were included: normal control, diabetic, diabetic rats treated with crude, butanol or dichloromethane fraction from BA (50 mg/kg BW) and diabetic rats treated with gliclazide as a reference drug for one month...
April 3, 2018: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/29679474/population-pharmacokinetics-of-gliclazide-in-normal-and-diabetic-rabbits
#6
Mastan Shaik, Shabana Shaik, Eswar Kumar Kilari
Gliclazide is a second-generation sulphonylurea drug widely used in the treatment of type 2 diabetes. However, there is no single report to describe the population pharmacokinetics of gliclazide in animal models. This study was aimed to evaluate the population pharmacokinetics (PK) of gliclazide in normal and alloxan-induced diabetic rabbits using nonlinear mixed effects modeling. A total of 90 New Zealand white rabbits were administered with 3 doses (4.13, 8.27 and 16.53 mg/kg b.wt) of gliclazide by an oral route...
April 21, 2018: Biopharmaceutics & Drug Disposition
https://www.readbyqxmd.com/read/29651307/effectiveness-of-gliclazide-mr-60-mg-in-the-management-of-type-2-diabetes-analyses-from-the-easydia-trial
#7
Lawrence A Leiter, Marina V Shestakova, Ilhan Satman
Background: Although the number of antihyperglycemic agents has expanded significantly, sulfonylureas (in particular gliclazide) remain an important option because of a variety of patient and health system factors. The large, real world, observational, and international EASYDia trial evaluated the effectiveness of gliclazide modified release (MR) 60 mg in individuals with type 2 diabetes with a broad range of diabetes history, body mass index (BMI) and background antihyperglycemic treatment...
2018: Diabetology & Metabolic Syndrome
https://www.readbyqxmd.com/read/29596951/a-randomized-controlled-trial-to-compare-the-effects-of-sulphonylurea-gliclazide-mr-modified-release-and-the-dpp-4-inhibitor-vildagliptin-on-glycemic-variability-and-control-measured-by-continuous-glucose-monitoring-cgm-in-brazilian-women-with-type-2-diabetes
#8
Andre Gustavo Daher Vianna, Claudio Silva Lacerda, Luciana Muniz Pechmann, Michelle Garcia Polesel, Emerson Cestari Marino, Jose Rocha Faria-Neto
AIMS: This study aims to evaluate whether there is a difference between the effects of vildagliptin and gliclazide MR (modified release) on glycemic variability (GV) in women with type 2 diabetes (T2DM) as evaluated by continuous glucose monitoring (CGM). METHODS: An open-label, randomized study was conducted in T2DM women on steady-dose metformin monotherapy which were treated with 50 mg vildagliptin twice daily or 60 to 120 mg of gliclazide MR once daily. CGM and GV indices calculation were performed at baseline and after 24 weeks...
March 26, 2018: Diabetes Research and Clinical Practice
https://www.readbyqxmd.com/read/29578647/bioequivalence-of-two-formulations-of-gliclazide-in-a-randomized-crossover-study-in-healthy-caucasian-subjects-under-fasting-conditions
#9
Diana Ioana Pop, Monica Oroian, Sandeep Bhardwaj, Adriana Marcovici, Arshad Khuroo, Ravi Kochhar, Laurian Vlase
This study aimed to investigate the bioequivalence of 2 formulations of gliclazide modified-release tablets 60 mg in 48 healthy Caucasian volunteers under fasting conditions. A test product, Gliclazide MR (Ranbaxy Laboratories Limited, now Sun Pharmaceutical Industries, India), was compared with a reference product, Diamicron MR (Servier, France). The study was performed under a single-dose, 2-treatment, 2-period, 2-sequence crossover design in a fasted condition with a washout period of 21 days. Blood samples were collected for 96 hours after drug administration...
March 26, 2018: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/29558784/alogliptin-and-gliclazide-similarly-increase-circulating-endothelial-progenitor-cells-in-type-2-diabetes-patients
#10
Roberto Negro, Eupremio Luigi Greco, Giacomo Greco
AIM: We investigated the effect of alogliptin and gliclazide on endothelial progenitor cells (EPCs) in type 2 diabetes. METHODS: Eighty patients with type 2 diabetes and HbA1c between 7.5% and 8.5% were randomized to receive either alogliptin (25 mg/daily) or gliclazide extended-release (30 mg/daily for HbA1c 7.5-8.0% and 60 mg/daily for HbA1c 8.0-8.5%) in combination with metformin for 4 months. At baseline and 4 months, clinical and laboratory parameters of EPCs were determined...
March 20, 2018: Experimental and Clinical Endocrinology & Diabetes
https://www.readbyqxmd.com/read/29547128/is-gliclazide-a-new-antidiabetic-drug-implicated-in-the-pathogenesis-of-ocular-mucous-membrane-pemphigoid
#11
Emanuele Cozzani, Giovanni Di Zenzo, Margherita Cioni, Sanja Javor, Marco Altieri, Luca Anselmi, Aurora Parodi
No abstract text is available yet for this article.
March 16, 2018: European Journal of Dermatology: EJD
https://www.readbyqxmd.com/read/29537664/the-pattern-of-prescribing-of-glucose-modulating-agents-for-type-2-diabetes-in-general-practices-in-england-2016-17
#12
Adrian H Heald, Mark Livingston, Zuzanna Bien, Gabriela Y C Moreno, Ian Laing, Mike Stedman
BACKGROUND: In the financial year 2016/17 there were 52.0 million items prescribed for diabetes at a total net ingredient cost of £983.7 million - up from 28.9 million prescription items and £572.4 million in 2006/07. Anti-diabetes drugs (British National Formulary section 6.1.2) make up 45.1 per cent of the total £983.7 million net ingredient cost of drugs used in diabetes and account for 72.0 per cent of prescription items for all diabetes prescribing. METHODS: We examined the way that agents licensed to treat type 2 diabetes were used across GP practices in England in the year 2016/2017...
March 14, 2018: International Journal of Clinical Practice
https://www.readbyqxmd.com/read/29535952/consensus-recommendations-on-sulfonylurea-and-sulfonylurea-combinations-in-the-management-of-type-2-diabetes-mellitus-international-task-force
#13
REVIEW
Sanjay Kalra, Silver Bahendeka, Rakesh Sahay, Sujoy Ghosh, Fariduddin Md, Abbas Orabi, Kaushik Ramaiya, Sameer Al Shammari, Dina Shrestha, Khalid Shaikh, Sachitha Abhayaratna, Pradeep K Shrestha, Aravinthan Mahalingam, Mazen Askheta, Aly Ahmed A Rahim, Fatimah Eliana, Hari K Shrestha, Sandeep Chaudhary, Nancy Ngugi, Jean Claude Mbanya, Than Than Aye, Tint Swe Latt, Zhanay A Akanov, Abbas Raza Syed, Nikhil Tandon, A G Unnikrishnan, S V Madhu, Ali Jawa, Subhankar Chowdhury, Sarita Bajaj, Ashok Kumar Das
For decades, sulfonylureas (SUs) have been important drugs in the antidiabetic therapeutic armamentarium. They have been used as monotherapy as well as combination therapy. Focus on newer drugs and concerns about the risk of severe hypoglycemia and weight gain with some SUs have led to discussion on their safety and utility. It has to be borne in mind that the adverse events associated with SUs should not be ascribed to the whole class, as many modern SUs, such as glimepiride and gliclazide modified release, are associated with better safety profiles...
January 2018: Indian Journal of Endocrinology and Metabolism
https://www.readbyqxmd.com/read/29516612/use-and-effectiveness-of-dapagliflozin-in-routine-clinical-practice-an-italian-multicentre-retrospective-study
#14
Gian Paolo Fadini, Giancarlo Zatti, Ileana Baldi, Daniele Bottigliengo, Agostino Consoli, Andrea Giaccari, Giorgio Sesti, Angelo Avogaro
In randomized controlled trials (RCTs), sodium-glucose co-transporter-2 (SGLT2) inhibitors have been shown to confer glycaemic and extra-glycaemic benefits. The DARWIN-T2D (DApagliflozin Real World evIdeNce in Type 2 Diabetes) study was a multicentre retrospective study designed to evaluate the baseline characteristics of patients receiving dapagliflozin vs those receiving selected comparators (dipeptidyl peptidase-4 inhibitors, gliclazide, or glucagon-like peptide-1 receptor agonists), and drug effectiveness in routine clinical practice...
March 8, 2018: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/29498478/interaction-of-sulfonylureas-with-liver-uptake-transporters-oatp1b1-and-oatp1b3
#15
Yu Chen, Lin Chen, Hong Zhang, Shibo Huang, Yuqing Xiong, Chunhua Xia
Sulfonylureas (SUs) such as glibenclamide, gliclazide, glimepiride, glipizide and gliquidone are one of the first oral medicines available for the treatment of type 2 diabetes and are widely used for the treatment of hyperglycaemia. The hepatic transporters, organic anion transporting polypeptide 1B1 (OATP1B1) and organic anion transporting polypeptide 1B3 (OATP1B3), play an important role in the disposition of a variety of drugs by mediating their uptake from blood into hepatocytes. Drug-drug interactions mediated by OATP1B1/1B3 may result in the hepatic transporting change for drug substrates...
March 2, 2018: Basic & Clinical Pharmacology & Toxicology
https://www.readbyqxmd.com/read/29460634/serum-metabolomics-study-of-gliclazide-modified-release-treated-type-2-diabetes-mellitus-patients-using-a-gas-chromatography-mass-spectrometry-method
#16
Yang Zhou, Cheng Hu, Xinjie Zhao, Ping Luo, Jingyi Lu, Qing Li, Miao Chen, Dandan Yan, Xin Lu, Hongwei Kong, Weiping Jia, Guowang Xu
Sulfonylureas are one of the commonly used drugs in type 2 diabetes mellitus (T2DM) but with considerable incidence of monotherapy failure. However, the mechanism of patients' drug response is unclear, and suitability evaluation biomarkers are in urgent need for precision medicine. In this study, a pseudotargeted gas chromatography-mass spectrometry method was employed to investigate the serum metabolic profiling of 66 significant responders and 24 nonsignificant responders at baseline and 16 weeks after gliclazide modified-release (MR) monotherapy...
April 6, 2018: Journal of Proteome Research
https://www.readbyqxmd.com/read/29425262/application-of-a-fast-separation-method-for-anti-diabetics-in-pharmaceuticals-using-monolithic-column-comparative-study-with-silica-based-c-18-particle-packed-column
#17
COMPARATIVE STUDY
A Hemdan, Omar Abdel-Aziz
Run time is a predominant factor in HPLC for quality control laboratories especially if there is large number of samples have to be analyzed. Working at high flow rates cannot be attained with silica based particle packed column due to elevated backpressure issues. The use of monolithic column as an alternative to traditional C-18 column was tested for fast separation of pharmaceuticals, where the results were very competitive. The performance comparison of both columns was tested for separation of anti-diabetic combination containing Metformin, Pioglitazone and Glimepiride using Gliclazide as an internal standard...
April 1, 2018: Journal of Chromatographic Science
https://www.readbyqxmd.com/read/29379326/effect-of-combined-gliclazide-metformin-treatment-on-oxidative-stress-lipid-profile-and-hepatorenal-functions-in-type-2-diabetic-patients
#18
Mansour Alsharidah, Metab Algeffari, Abdel-Moneim Hafez Abdel-Moneim, Mohamed Faisal Lutfi, Haila Alshelowi
Background: Type 2 diabetes is a chronic condition that requires pharmacotherapy interventions. Metformin and gliclazide are widely used drugs in monotherapy. However, their complementary action made utilization of the combination of these drugs an appealing approach. Aims: The study compared major therapeutic potentials of combined metformin/gliclazide treatment over metformin monotherapy based on the following parameters: oxidative stress, lipid profile, and hepatorenal functions...
January 2018: Saudi Pharmaceutical Journal: SPJ: the Official Publication of the Saudi Pharmaceutical Society
https://www.readbyqxmd.com/read/29337033/gliclazide-a-k-atp-channel-blocker-inhibits-vascular-smooth-muscle-cell-proliferation-through-the-camkk%C3%AE-ampk-pathway
#19
Kyung Young Lee, Jae-Ryong Kim, Hyoung Chul Choi
Gliclazide, a sulfonylurea that is widely used to treat type II-diabetes, specifically blocks KATP channels and recombinant smooth muscle (SUR2B/Kir6.1) KATP channels with high potency. Furthermore, it exerts antioxidant properties and inhibits tumor cell proliferation. In this study, we investigated the inhibitory effect of gliclazide on vascular smooth muscle cell (VSMC) proliferation and tried to identify the underlying signaling pathway. We first investigated the effect of gliclazide-induced AMP-activated protein kinase (AMPK) activation on the proliferation of VSMCs...
March 2018: Vascular Pharmacology
https://www.readbyqxmd.com/read/29327815/no-impact-of-pre-existing-cardiovascular-disease-on-prescribing-patterns-of-sulphonylureas-in-denmark-a-registry-based-nationwide-study
#20
Malin Nilsson, Jørgen Rungby, Nathan Lassota, Andreas D Jørgensen, Rikke Ibsen, Jakob Kjellberg
Uncertainty exists regarding cardiovascular (CV) safety of sulphonylureas (SUs) as reflected in package labels and treatment guidelines. This study evaluated clinical treatment practice for SUs by analysing prescription patterns for SUs relative to patient history of CV disease (CVD). Patients in Denmark initiating treatment with SU or other anti-hyperglycaemic drugs during 2006-12 were retrospectively identified using national health registries. Pre-existing (previous 12 years) overall CVD, coronary heart disease (CHD) and myocardial infarction (MI) were subsequently identified...
January 12, 2018: Basic & Clinical Pharmacology & Toxicology
keyword
keyword
51779
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"